FI95262B - Förfarande för framställning av nya fosfolipidderivat - Google Patents

Förfarande för framställning av nya fosfolipidderivat Download PDF

Info

Publication number: FI95262B
Authority: FI; Finland
Prior art keywords: phosphoric acid; decyloxypropyl; mono; ester; propyl
Prior art date: 1989-09-02

Application number

FI904305A

Other languages

English (en)

Finnish (fi)

Other versions

FI904305A0 (sv

FI95262C (sv

Inventor

Elmar Bosies

Dieter Herrmann

Harald Zilch

Edith Koch

Original Assignee

Boehringer Mannheim Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-02

Filing date

1990-08-31

Publication date

1995-09-29

1990-08-31 Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh

1990-08-31 Publication of FI904305A0 publication Critical patent/FI904305A0/sv

1995-09-29 Publication of FI95262B publication Critical patent/FI95262B/sv

1996-01-10 Application granted granted Critical

1996-01-10 Publication of FI95262C publication Critical patent/FI95262C/sv

Links

238000002360 preparation method Methods 0.000 title claims abstract description 10
238000000034 method Methods 0.000 title claims description 11
150000003904 phospholipids Chemical class 0.000 title abstract description 11
-1 sulphinyl Chemical group 0.000 claims abstract description 27
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 8
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 6
125000002947 alkylene group Chemical group 0.000 claims abstract description 5
150000003839 salts Chemical class 0.000 claims abstract description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 4
229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
239000001301 oxygen Substances 0.000 claims abstract description 4
239000001257 hydrogen Substances 0.000 claims abstract description 3
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
230000003287 optical effect Effects 0.000 claims abstract 3
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 56
NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 56
150000002148 esters Chemical class 0.000 claims description 48
150000001875 compounds Chemical class 0.000 claims description 31
229960001231 choline Drugs 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 10
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 9
125000000217 alkyl group Chemical group 0.000 claims description 7
125000001424 substituent group Chemical group 0.000 claims description 6
239000007795 chemical reaction product Substances 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
239000011593 sulfur Substances 0.000 claims description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000004414 alkyl thio group Chemical group 0.000 claims description 3
229910021529 ammonia Inorganic materials 0.000 claims description 3
239000002516 radical scavenger Substances 0.000 claims description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
238000007710 freezing Methods 0.000 claims description 2
230000008014 freezing Effects 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
239000003960 organic solvent Substances 0.000 claims description 2
239000000047 product Substances 0.000 claims description 2
238000010992 reflux Methods 0.000 claims description 2
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
229920002114 octoxynol-9 Polymers 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 6
229920006395 saturated elastomer Polymers 0.000 abstract description 6
230000000840 anti-viral effect Effects 0.000 abstract description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000004406 C3-C8 cycloalkylene group Chemical group 0.000 abstract 1
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
239000000203 mixture Substances 0.000 description 15
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
239000003921 oil Substances 0.000 description 11
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
239000000243 solution Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
239000007858 starting material Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 5
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000003480 eluent Substances 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
229960002555 zidovudine Drugs 0.000 description 3
MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 2
HMHHAAZRWXKITO-UHFFFAOYSA-N 2-amino-3-dodecylsulfanylpropanoic acid Chemical compound CCCCCCCCCCCCSCC(N)C(O)=O HMHHAAZRWXKITO-UHFFFAOYSA-N 0.000 description 2
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
235000019871 vegetable fat Nutrition 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
JSKHDTMNMLIHFR-UHFFFAOYSA-N (3-bromo-2-decoxypropyl) benzoate Chemical compound CCCCCCCCCCOC(CBr)COC(=O)C1=CC=CC=C1 JSKHDTMNMLIHFR-UHFFFAOYSA-N 0.000 description 1
KIHQZLPHVZKELA-UHFFFAOYSA-N 1,3-dibromopropan-2-ol Chemical compound BrCC(O)CBr KIHQZLPHVZKELA-UHFFFAOYSA-N 0.000 description 1
VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
239000005968 1-Decanol Substances 0.000 description 1
PBLNBZIONSLZBU-UHFFFAOYSA-N 1-bromododecane Chemical compound CCCCCCCCCCCCBr PBLNBZIONSLZBU-UHFFFAOYSA-N 0.000 description 1
QWVCIORZLNBIIC-UHFFFAOYSA-N 2,3-dibromopropan-1-ol Chemical compound OCC(Br)CBr QWVCIORZLNBIIC-UHFFFAOYSA-N 0.000 description 1
NPKKFQUHBHQTSH-UHFFFAOYSA-N 2-(decoxymethyl)oxirane Chemical compound CCCCCCCCCCOCC1CO1 NPKKFQUHBHQTSH-UHFFFAOYSA-N 0.000 description 1
SBMUNILHNJLMBF-UHFFFAOYSA-N 2-chloro-1,3,2$l^{5}-dioxaphospholane 2-oxide Chemical compound ClP1(=O)OCCO1 SBMUNILHNJLMBF-UHFFFAOYSA-N 0.000 description 1
VDYUESQCNSYZDC-UHFFFAOYSA-N 5-(decoxymethyl)-2-phenyl-1,3-dioxane Chemical compound O1CC(COCCCCCCCCCC)COC1C1=CC=CC=C1 VDYUESQCNSYZDC-UHFFFAOYSA-N 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000248349 Citrus limon Species 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920000388 Polyphosphate Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000700605 Viruses Species 0.000 description 1
210000002945 adventitial reticular cell Anatomy 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
150000002118 epoxides Chemical class 0.000 description 1
NLUIHMBYNJACAQ-UHFFFAOYSA-N ethyl 2-amino-2-sulfanylpentadecanoate Chemical compound CCCCCCCCCCCCCC(N)(S)C(=O)OCC NLUIHMBYNJACAQ-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
GNVRJGIVDSQCOP-UHFFFAOYSA-N n-ethyl-n-methylethanamine Chemical group CCN(C)CC GNVRJGIVDSQCOP-UHFFFAOYSA-N 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 1
125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001205 polyphosphate Substances 0.000 description 1
235000011176 polyphosphates Nutrition 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
229940064914 retrovir Drugs 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
125000005624 silicic acid group Chemical class 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
CCIDWXHLGNEQSL-UHFFFAOYSA-N undecane-1-thiol Chemical compound CCCCCCCCCCCS CCIDWXHLGNEQSL-UHFFFAOYSA-N 0.000 description 1
JUKPJGZUFHCZQI-UHFFFAOYSA-N undecanoyl chloride Chemical compound CCCCCCCCCCC(Cl)=O JUKPJGZUFHCZQI-UHFFFAOYSA-N 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

FI904305A 1989-09-02 1990-08-31 Förfarande för framställning av nya fosfolipidderivat FI95262C (sv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3929217A DE3929217A1 (de)	1989-09-02	1989-09-02	Verwendung von phospholipid-derivaten als antivirale arzneimittel und neue phospholipide
DE3929217		1989-09-02

Publications (3)

Publication Number	Publication Date
FI904305A0 FI904305A0 (sv)	1990-08-31
FI95262B true FI95262B (sv)	1995-09-29
FI95262C FI95262C (sv)	1996-01-10

Family

ID=6388525

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI904305A FI95262C (sv)	1989-09-02	1990-08-31	Förfarande för framställning av nya fosfolipidderivat

Country Status (21)

Country	Link
US (1)	US5158942A (sv)
EP (1)	EP0416401B1 (sv)
JP (1)	JP3009196B2 (sv)
KR (1)	KR910006309A (sv)
AT (1)	ATE144776T1 (sv)
AU (1)	AU633351B2 (sv)
CA (1)	CA2023944C (sv)
DD (1)	DD297561A5 (sv)
DE (2)	DE3929217A1 (sv)
DK (1)	DK0416401T3 (sv)
ES (1)	ES2095848T3 (sv)
FI (1)	FI95262C (sv)
GR (1)	GR3022038T3 (sv)
HU (1)	HU208830B (sv)
IE (1)	IE903160A1 (sv)
IL (1)	IL95498A0 (sv)
MX (1)	MX22124A (sv)
NO (1)	NO903821L (sv)
NZ (1)	NZ235067A (sv)
PT (1)	PT95166A (sv)
ZA (1)	ZA906950B (sv)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2001401A1 (en) *	1988-10-25	1990-04-25	Claude Piantadosi	Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US6602861B1 (en) *	1992-04-16	2003-08-05	Research Corporation Technologies, Inc.	Acylated phospholipid drugs
JP3961029B2 (ja) *	1992-06-24	2007-08-15	博木戸	インフルエンザウィルス感染防止剤
WO1994002153A1 (en) *	1992-07-22	1994-02-03	Boehringer Mannheim Gmbh	Use of sulphur containing phospholipids for treating leishmaniasis
CA2164717C (en) *	1993-06-10	2009-10-20	Louis S. Kucera	Method of combatting hepatitis b virus infection
US7135584B2 (en)	1995-08-07	2006-11-14	Wake Forest University	Lipid analogs for treating viral infections
DE69535758D1 (de)	1994-08-29	2008-07-03	Univ Wake Forest	Lipid-analoge zur behandlung von viralen infektionen
DE19538402A1 (de) *	1995-10-14	1997-04-17	Boehringer Mannheim Gmbh	Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel
TW343975B (en) *	1995-12-15	1998-11-01	Boehringer Mannheim Gmbh	New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
US7026469B2 (en)	2000-10-19	2006-04-11	Wake Forest University School Of Medicine	Compositions and methods of double-targeting virus infections and cancer cells
US7309696B2 (en)	2000-10-19	2007-12-18	Wake Forest University	Compositions and methods for targeting cancer cells
WO2003021959A1 (en)	2001-08-31	2003-03-13	Thomson Licensing Sa	Sequence counter for an audio visual stream
WO2019025324A1 (en) *	2017-08-03	2019-02-07	Karl-Franzens-Universität Graz	ANALOGUES OF PHOSPHOLIPIDS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3025804C2 (de) *	1980-07-08	1985-09-05	A. Nattermann & Cie GmbH, 5000 Köln	1-S-Alkyl-2-0-acyl-3-phosphocholin-1-mercapto-2,3-propandiole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
EP0050327B1 (de) *	1980-10-21	1984-06-20	Roche Diagnostics GmbH	Neue schwefelhaltige Phospholipide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3127503A1 (de) *	1981-07-11	1983-02-17	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3204735A1 (de) *	1982-02-11	1983-08-18	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
ATE45744T1 (de) *	1984-07-25	1989-09-15	Ciba Geigy Ag	Phosphatidylverbindungen, verfahren zu ihrer herstellung und ihre verwendung.
DE3638126A1 (de) *	1986-11-08	1988-05-11	Nattermann A & Cie	Mercaptoalkanolphospholipide und deren derivate, verfahren zu ihrer herstellung und ihre verwendung als wirkstoffe in arzneimitteln
JPS6429319A (en) *	1987-07-23	1989-01-31	Toyama Chemical Co Ltd	Antiviral agent containing lysolecithin and phospholipid
IL84387A0 (en) *	1987-11-06	1990-02-09	Rapaport Erich	Pharmaceutical compositions containing a substituted phosphatide
DE3906952A1 (de) *	1989-03-04	1990-09-06	Boehringer Mannheim Gmbh	(3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel

1989
- 1989-09-02 DE DE3929217A patent/DE3929217A1/de not_active Withdrawn
1990
- 1990-08-23 US US07/572,475 patent/US5158942A/en not_active Expired - Lifetime
- 1990-08-24 CA CA002023944A patent/CA2023944C/en not_active Expired - Fee Related
- 1990-08-25 AT AT90116298T patent/ATE144776T1/de not_active IP Right Cessation
- 1990-08-25 EP EP90116298A patent/EP0416401B1/de not_active Expired - Lifetime
- 1990-08-25 DE DE59010550T patent/DE59010550D1/de not_active Expired - Fee Related
- 1990-08-25 DK DK90116298.2T patent/DK0416401T3/da active
- 1990-08-25 ES ES90116298T patent/ES2095848T3/es not_active Expired - Lifetime
- 1990-08-27 IL IL95498A patent/IL95498A0/xx unknown
- 1990-08-28 MX MX2212490A patent/MX22124A/es unknown
- 1990-08-28 NZ NZ235067A patent/NZ235067A/xx unknown
- 1990-08-29 HU HU905684A patent/HU208830B/hu not_active IP Right Cessation
- 1990-08-31 DD DD90343764A patent/DD297561A5/de not_active IP Right Cessation
- 1990-08-31 PT PT95166A patent/PT95166A/pt not_active Application Discontinuation
- 1990-08-31 FI FI904305A patent/FI95262C/sv not_active IP Right Cessation
- 1990-08-31 AU AU62064/90A patent/AU633351B2/en not_active Ceased
- 1990-08-31 ZA ZA906950A patent/ZA906950B/xx unknown
- 1990-08-31 IE IE316090A patent/IE903160A1/en unknown
- 1990-08-31 NO NO90903821A patent/NO903821L/no unknown
- 1990-09-01 KR KR1019900013857A patent/KR910006309A/ko not_active Application Discontinuation
- 1990-09-03 JP JP2230756A patent/JP3009196B2/ja not_active Expired - Fee Related
1996
- 1996-12-13 GR GR960403465T patent/GR3022038T3/el unknown

Also Published As

Publication number	Publication date
DE59010550D1 (de)	1996-12-05
CA2023944A1 (en)	1991-03-03
EP0416401A2 (de)	1991-03-13
DE3929217A1 (de)	1991-03-07
DD297561A5 (de)	1992-01-16
JP3009196B2 (ja)	2000-02-14
ZA906950B (en)	1991-06-26
GR3022038T3 (en)	1997-03-31
HUT54696A (en)	1991-03-28
HU208830B (en)	1994-01-28
ES2095848T3 (es)	1997-03-01
AU6206490A (en)	1991-03-07
FI904305A0 (sv)	1990-08-31
US5158942A (en)	1992-10-27
IE903160A1 (en)	1991-03-13
JPH0393787A (ja)	1991-04-18
EP0416401B1 (de)	1996-10-30
CA2023944C (en)	2001-07-31
NZ235067A (en)	1992-12-23
NO903821D0 (no)	1990-08-31
MX22124A (es)	1993-11-01
EP0416401A3 (en)	1992-04-22
AU633351B2 (en)	1993-01-28
KR910006309A (ko)	1991-04-29
NO903821L (no)	1991-03-04
FI95262C (sv)	1996-01-10
ATE144776T1 (de)	1996-11-15
DK0416401T3 (da)	1997-04-07
IL95498A0 (en)	1991-06-30
PT95166A (pt)	1991-05-22

Publication	Publication Date	Title
FI95262B (sv)	1995-09-29	Förfarande för framställning av nya fosfolipidderivat
EP0050327B1 (de)	1984-06-20	Neue schwefelhaltige Phospholipide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
AU2008242830B2 (en)	2015-08-20	Lipoic acid derivatives
PL198394B1 (pl)	2008-06-30	Związki pochodne arylosulfonoanilidomocznika, ich zastosowanie oraz zawierające je kompozycje farmaceutyczne
US20030149021A1 (en)	2003-08-07	Piperazine mono(dithio)carbamate ester compounds and analogs thereof: preparation method and uses thereof
FR2528847A1 (fr)	1983-12-23	Produits nouveaux de la classe des carbapenems et leur application en tant qu'antibiotiques
CN101076525B (zh)	2011-07-27	用作肿瘤坏死因子-α抑制剂的稠合三环化合物
GB2111482A (en)	1983-07-06	Azetidine medicaments
AU657920B2 (en)	1995-03-30	Benzimidazole derivatives, process for their preparation and their application
EP0009882B1 (en)	1982-03-03	2'-deoxy-5-fluorouridine derivatives, a process for producing the same and antitumor agents comprising the same
DE69708340T2 (de)	2002-05-16	Arylsulfonylimidazolon-derivate als antitumormittel
CH648852A5 (de)	1985-04-15	Oxazaphosphorin-4-thio-alkansulfonsaeuren, ihre neutralen salze, verfahren zur herstellung derselben und diese enthaltenden pharmazeutischen praeparate.
DE69226703T2 (de)	1999-02-18	Imidazo (4,5-c)pyridinderivate als paf antagonisten
GB2168349A (en)	1986-06-18	Intermediates for vinylthioacetamido oxacephalosporin derivatives
CS240973B2 (en)	1986-03-13	Production method of benzamide derivatives
FR2549063A1 (fr)	1985-01-18	Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
PL138373B1 (en)	1986-09-30	Process for preparing novel substituted thiazolidinyl esters of mineral acids
CN114075255A (zh)	2022-02-22	一种糖基供体及其在制备糖苷中的用途
CN101119971A (zh)	2008-02-06	环庚[b]吡啶-3-羰基胍衍生物及含有该衍生物的医药品
JPH0148913B2 (sv)	1989-10-20
US4281118A (en)	1981-07-28	Aminoalkylsulfides, aminoalkylsulfoxides, and aminoalkylsulfones
JP3951016B2 (ja)	2007-08-01	非対称ジスルフィド化合物とその製造方法
FR2489825A1 (fr)	1982-03-12	4-carbamoyloxy-oxazaphosphorines, procede pour leur preparation et compositions pharmaceutiques qui les contiennent
IL96730A (en)	1996-10-31	2-Formylbenzylphosphonic acid derivatives their preparation and pharmaceutical compositions containing them for the treatment of diseases caused by viruses
NL8400015A (nl)	1984-08-01	Penem-esters.

Legal Events

Date	Code	Title	Description
1995-09-01	BB	Publication of examined application
2004-08-31	FG	Patent granted	Owner name: HEIDELBERG PHARMA HOLDING GMBH
2005-02-28	MA	Patent expired